Michael Holmes was Promoted as Senior Vice President and Chief Technology Officer at Sangamo

Date of management change: May 03, 2018 

What Happened?

Richmond, CA-based Sangamo Promoted Michael Holmes as Senior Vice President and Chief Technology Officer

 

About the Company

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.

 

About the Person

Michael Holmes is Senior Vice President and Chief Technology Officer at Sangamo. Previously, Michael held various senior IT leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Slepicka Kirstin, John Biji, Junko Nagano, Devinney Lauren, Dakin Bryce, Cossaboom Jim, Beall Gregg, Zachman Michael, Elhalaby Hazem, Mullins Brendan, Trotter Rob

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.